Stifel Nicolaus reiterated their hold rating on shares of Exelixis, Inc. (NASDAQ:EXEL) in a report released on Thursday morning. They currently have a $26.00 price objective on the biotechnology company’s stock.

Other equities research analysts have also recently issued research reports about the stock. TheStreet raised shares of Exelixis from a c rating to a b- rating in a research report on Monday, August 7th. BidaskClub raised shares of Exelixis from a hold rating to a buy rating in a research report on Friday, June 23rd. SunTrust Banks, Inc. initiated coverage on shares of Exelixis in a research report on Thursday, July 13th. They set a buy rating and a $33.00 price target for the company. Piper Jaffray Companies reissued a buy rating and set a $29.00 price target on shares of Exelixis in a research report on Thursday, August 3rd. Finally, Zacks Investment Research cut shares of Exelixis from a strong-buy rating to a hold rating in a research report on Wednesday, June 28th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. The company has an average rating of Buy and a consensus price target of $25.57.

Exelixis (EXEL) traded up 1.21% on Thursday, reaching $25.97. 4,567,016 shares of the company’s stock were exchanged. Exelixis has a one year low of $10.04 and a one year high of $29.50. The firm has a 50 day moving average price of $27.14 and a 200 day moving average price of $23.23. The firm has a market cap of $7.63 billion, a PE ratio of 131.16 and a beta of 1.97.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. The company had revenue of $99.01 million during the quarter, compared to analysts’ expectations of $85.27 million. During the same quarter in the prior year, the company earned ($0.15) EPS. The firm’s revenue was up 173.1% on a year-over-year basis. On average, equities analysts anticipate that Exelixis will post $0.26 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Exelixis’ (EXEL) “Hold” Rating Reiterated at Stifel Nicolaus” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://theolympiareport.com/2017/09/10/exelixis-exel-hold-rating-reiterated-at-stifel-nicolaus.html.

Several large investors have recently bought and sold shares of EXEL. Nationwide Fund Advisors lifted its position in shares of Exelixis by 61.2% in the 1st quarter. Nationwide Fund Advisors now owns 284,279 shares of the biotechnology company’s stock worth $6,160,000 after purchasing an additional 107,889 shares during the period. Strs Ohio lifted its position in shares of Exelixis by 37.8% in the 1st quarter. Strs Ohio now owns 47,400 shares of the biotechnology company’s stock worth $1,027,000 after purchasing an additional 13,000 shares during the period. Russell Investments Group Ltd. lifted its position in shares of Exelixis by 2.8% in the 1st quarter. Russell Investments Group Ltd. now owns 624,628 shares of the biotechnology company’s stock worth $13,535,000 after purchasing an additional 17,070 shares during the period. Wells Fargo & Company MN lifted its position in shares of Exelixis by 167.1% in the 1st quarter. Wells Fargo & Company MN now owns 1,460,194 shares of the biotechnology company’s stock worth $31,642,000 after purchasing an additional 913,454 shares during the period. Finally, Great West Life Assurance Co. Can lifted its position in shares of Exelixis by 26.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 28,342 shares of the biotechnology company’s stock worth $613,000 after purchasing an additional 6,000 shares during the period. 79.20% of the stock is owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.